Patent: 8,263,554
✉ Email this page to a colleague
Summary for Patent: 8,263,554
Title: | Methods of using GLP-1 receptor agonists to treat pancreatitis |
Abstract: | The disclosure provides the use of GLP-1 receptor agonist compounds to treat pancreatitis (e.g., acute, chronic, hemorrhagic, necrotizing) in patients. The disclosure also provides the use of GLP-1 receptor agonist compounds to reduce elevated plasma amylase and/or lipase concentrations in patients. An exemplary GLP-1 receptor agonist compound is exenatide. |
Inventor(s): | Tatarkiewicz; Krystyna (San Diego, CA), Parkes; David G. (Del Mar, CA), Roy; Denis (Vista, CA), Gedulin; Bronislava (Del Mar, CA) |
Assignee: | Amylin Pharmaceuticals, Inc. (San Diego, CA) |
Application Number: | 13/155,211 |
Patent Claims: | see list of patent claims |
Details for Patent 8,263,554
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Glaxosmithkline Llc | TANZEUM | albiglutide | For Injection | 125431 | 04/15/2014 | ⤷ Try a Trial | 2030-06-09 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/18/2014 | ⤷ Try a Trial | 2030-06-09 |
Eli Lilly And Company | TRULICITY | dulaglutide | Injection | 125469 | 09/04/2020 | ⤷ Try a Trial | 2030-06-09 |
Sanofi-aventis U.s. Llc | ADLYXIN | lixisenatide | Injection | 208471 | 07/27/2016 | ⤷ Try a Trial | 2030-06-09 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |